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Abstract
Background: Renal function declines according to age and vascular 
risk factors, whereas few data are available regarding genetically-
mediated effects of anti-hypertensives over renal function.
Objective: To estimate urea and creatinine variations in dementia due 
to Alzheimer disease (AD) by way of a pharmacogenetic analysis of the 
anti-hypertensive effects of angiotensin-converting enzyme inhibitors 
(ACEis).
Methods: Consecutive outpatients older than 60 years-old with AD 
and no history of kidney transplant or dialytic therapy were recruited 
for prospective correlations regarding variations in fasting blood levels 
of urea and creatinine in one year, considering ACE genotypes of 
rs1800764 and rs4291 and their respective haplotypes, and treatment 
with ACEis along with blood pressure variations.
Results: For 190 patients, 152 had arterial hypertension, and 122 used 
ACEis. Minor allele frequencies were 0.492 for rs1800764-C and 0.337 
for rs4291-T, both in Hardy-Weinberg equilibrium. There were no 
overall significant yearly variations in levels of urea and creatinine, 
but their concurrent variations were positively correlated (ρ <0.0001). 
Each A allele of rs4291 led to an yearly urea increase of 3.074 mg/
dL, and an yearly creatinine increase of 0.044 mg/dL, while the use 
of ACEis was protective regarding creatinine variations. The use of 
ACEis was also protective for carriers of rs1800764-CT/rs4291-AA, 
while carriers of rs1800764-CT/rs4291-AT had steeper reductions in 
creatinine levels, particularly when they were treated with ACEis.
Conclusions: Effects of ACEis over creatinine variations are 
genetically mediated and independent of blood pressure variations in 
older people with AD.
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Resumen
Antecedentes: El deterioro de la función renal depende de la edad 
y los factores vasculares. La literatura sobre los efectos de fármacos 
antihipertensivos mediada genéticamente en la función renal es 
pobre.
Objetivo: Estimar las variaciones de urea y creatinina a través del 
análisis farmacogenético de los efectos antihipertensivos de los 
inhibidores de la enzima convertidora de angiotensina (iECA) en 
pacientes con demencia debido a la enfermedad de Alzhaimer.
Métodos: Fueron reclutados pacientes consecutivos mayores de 60 
años de edad con enfermedad de Alzheimer y sin antecedentes de 
trasplante renal o diálisis. Se determinaron correlaciones prospectivas 
durante un año entre los cambios en los niveles sanguíneos de urea y 
creatinina, considerando genotipos y haplotipos de ACE (rs1800764 
y rs4291) y el tratamiento con iECA a y las variaciones en la presión 
arterial.
Resultados: De 190 pacientes, 152 presenaron hipertensión, 122 
usaron iECA. Las frecuencias de alelos polimórficos fueron de 0.492 
para rs1800764-C y 0.337 para rs4291-T, los dos alelos en equilibrio 
de Hardy-Weinberg. No se determinaron fluctuaciones anuales 
significativas en los niveles de urea o creatinina, pero sus variaciones 
concomitantes se asociaron fuertemente (ρ= <0.0001). Cada alelo A 
de rs4291 condujo a aumentos anuales de 3.074 mg/dL en urea y 0.044 
mg/dL en creatinina, mientras que el uso de iECA fue protector para 
las variaciones en la creatinina. El uso de iECA también fue protector 
para las personas con rs1800764-CT/rs4291-AA, mientras que los 
portadores de rs1800764-CT/rs4291-AT tuvieron reducciones de 
creatinina más altas, particularmente cuando se usó iECA.
Conclusión: Los efectos de iECA en la variación de la creatinina 
son genéticamente mediadas e independiente de las variaciones en 
la presión arterial en pacientes de edad avanzada con la enfermedad 
de Alzheimer.
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Introduction
Renal function declines with age and according to the burden 
of vascular risk factors, while serum creatinine and proteinuria 
have been associated with late life incident all-cause dementia1. 
The angiotensin-converting enzyme modulates the generation of 
angiotensin II, a vasoconstrictor that may lead to glomerulopathy 
by increased intraglomerular hydraulic pressure that can be 
improved by treatment with angiotensin-converting enzyme 
inhibitors2. Both low and high glomerular filtration rates may be 
useful markers for mortality and cardiovascular events3, while 
genetic influences might be important to mediate those risks.
Genetic effects account for most of the variance in serum levels of 
the angiotensin-converting enzyme4. The two functional variants 
of the ACE gene with the most significant effects for higher activity 
of the angiotensin-converting enzyme are rs1800764 and rs42915. 
They also affect risk6 and age at onset7 of the amnestic phenotype 
of dementia due to Alzheimer disease, as well as cognitive decline5: 
rs1800764 is located at ∼0.2 kb from the transcription start site in 
the promoter of ACE in 17q23, while rs4291 is at ∼3.8 kb from the 
same site6. Both variants have local boosting effects upon serum 
angiotensin-converting enzyme levels, and have been strongly 
linked with risk of arterial hypertension8,9, particularly for patients 
with coronary artery disease and cerebrovascular disease10.
An earlier study had already demonstrated that the A1166C 
polymorphism of the AT1R gene may increase the anti-hypertensive 
effect of Benazepril11. Nevertheless, pharmacogenetic effects of 
angiotensin-converting enzyme inhibitors over the age-related 
decline in renal function have never been studied before, even 
though they seem to boost genetically mediated neuroprotective 
effects in dementia due to Alzheimer disease 5 while also 
benefitting learning abilities in healthy older individuals12. We 
aimed to estimate the variation in one year of levels of urea and 
creatinine in older people with dementia due to Alzheimer disease 
by way of a pharmacogenetic analysis of the effects of angiotensin-
converting enzyme inhibitors, while taking into account possible 
impacts of systolic and diastolic blood pressure disparities over 
such variations.
Materials and Methods
Participants and clinical assessment
Consecutive outpatients with dementia due to Alzheimer disease 
according to National Institute on Aging - Alzheimer’s Association 
criteria13 were prospectively recruited from October 2010 to May 
2014 at the Behavioural Neurology Section of our university 
hospital. Each patient had to be at least 60 years-old, and could 
not have history of kidney transplant or be receiving any form of 
dialytic therapy. All patients were followed for one year.
After diagnostic confirmation, all patients had at least three 
yearly consultations, and were assessed for age, gender, arterial 
hypertension, and use of angiotensin-converting enzyme 
inhibitors. For statistics, only the first and the last evaluations 
were taken into account, the last evaluation one year apart from 
the first one. Fasting urea and creatinine levels were measured 
from venous blood samples at the beginning and at the end of the 
follow-up after one year. Blood pressure was measured in every 
evaluation after the participant sat resting for 5 min in a warm 
and quiet room, while the diagnosis of arterial hypertension 
followed the JNC 7 report14. All efforts were directed to control 
blood pressure for all patients rather than just lowering systolic 
and diastolic levels.
Outcome measures
The primary outcome measure was the variation in one year of 
levels of urea and creatinine, taking the following independent 
variables into account: use of an angiotensin-converting enzyme 
inhibitor and ACE genotypes or haplotypes. In secondary analyses, 
the impacts of systolic and diastolic blood pressure variations 
in one year over variations in levels of urea and creatinine were 
assessed.
Genotyping procedures
After blood samples were collected from all patients in tubes 
with ethylenediaminetetraacetic acid 0.1%, genomic DNA was 
extracted using a standard salting-out procedure. Genotyping was 
undertaken by way of Real-Time Polymerase Chain Reactions 
using TaqManENT#174; SNP Genotyping Assays on the 
Applied Biosystems 7500 Fast Real-Time PCR System (Applied 
BiosystemsENT#174;, CA, USA), following the standard protocols 
of the manufacturer. Presence ofACE genotypes of rs1800764 or 
rs4291, or their represented haplotypes, was correlated with anti-
hypertensive treatment using angiotensin-converting enzyme 
inhibitors. All genotyping procedures were carried out only after 
clinical data were collected from all patients.
Statistical analysis
One-way analysis of variance with post-hoc Tukey test was 
employed for variations of blood pressure, urea and creatinine 
in one year, taking initial and final values into account. The 
Hardy-Weinberg equilibrium for  ACE  genotypes was estimated 
by way of the  Chi-square test. Multiple linear regressions were 
employed for comparisons within each patient group concerning 
variations of urea and creatinine in one year, with two degrees 
of freedom:  ACE  genotypes or haplotypes, and use or not of 
an angiotensin-converting enzyme inhibitor. Simple linear 
regressions were used for correlations between yearly variations in 
urea and creatinine, and yearly variations in systolic and diastolic 
blood pressure, so that genetically mediated effects of angiotensin-
converting enzyme inhibitors over urea and creatinine variations 
could be evaluated independently of their blood pressure lowering 
properties. The threshold of significance was set at p= <0.05.
Ethical considerations
This study is part of the research project 1067/10 (CAAE 
0540.0.174.000-10) approved by the Ethics Committee of our 
university hospital in August 2010. Procedures of the study were 
in accordance with the Declaration of Helsinki. All invited patients 
and their legal representatives agreed to participate on the research 
and signed the Informed Consent Form before the evaluation.
Results
A total of 217 patients were included in this study. During follow-
up, 14 patients (6.5%) passed away, 11 patients (5.1%) abandoned 
the study, and 2 patients (0.9%) were excluded due to incomplete 
clinical data, resulting in a final sample of 190 patients.
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Table 1 shows demographic and clinical results for all patients. 
Less than two thirds of them used angiotensin-converting enzyme 
inhibitors for blood pressure control. Systolic and diastolic blood 
pressure levels were significantly lowered after one year, while no 
significant overall variations were found for urea or creatinine 
levels in venous blood.
Table 2 shows genotyping results for all patients. Minor allele 
frequencies were 0.492 for rs1800764 (C) and 0.337 for rs4291 
(T), with both variants in Hardy-Weinberg equilibrium. Of nine 
possible ACE haplotypes, six were represented in the sample.
Table 3 shows urea and creatinine variations in one year according 
to genotype and haplotype frequencies for ACE polymorphisms 
and the use or not of angiotensin-converting enzyme inhibitors. 
No significant impacts over urea or creatinine variations were 
found regarding any independent genotypes of rs1800764. The 
presence of each A allele of rs4291 led to an yearly urea increase 
of 3.074 mg/dL, and an yearly creatinine increase of 0.044 mg/
dL, while the use of angiotensin-converting enzyme inhibitors 
was protective regarding creatinine variations. With regard 
to creatinine variations for all studied haplotypes, the use of 
angiotensin-converting enzyme inhibitors was protective for 
carriers of rs1800764 CT / rs4291 AA, while carriers of rs1800764 
CT / rs4291 AT had steeper reductions in blood creatinine levels, 
particularly when they were treated with angiotensin-converting 
enzyme inhibitors.
Overall, no correlations were found between urea variations and 
variations in systolic blood pressure (p= 0.212) or diastolic blood 
pressure (p= 0.098) in one year. Likewise, no correlations were 
found between creatinine variations and variations in systolic 
blood pressure (p= 0.767) or diastolic blood pressure (p= 0.713) 
in one year. Nevertheless, variations of urea and creatinine in one 
year were positively correlated with each other (p= <0.0001).
Discussion
Our results showed that, despite the absence of significant overall 
variations for urea or creatinine, carriers of the A allele of rs4291 
had higher age-related increases in urea and creatinine in one year, 
while the use of angiotensin-converting enzyme inhibitors was 
protective regarding creatinine variations. The use of angiotensin-
converting enzyme inhibitors was also protective regarding 
creatinine variations for carriers of rs1800764 CT / rs4291 AA, but 
it was deleterious for carriers of rs1800764 CT / rs4291 AT. These 
results were independent of yearly variations in systolic or diastolic 
blood pressure, and it seems that rs4291 is more important for 
urea and creatinine variations than rs1800764.
The A allele of rs4291 has been associated with increased serum 
levels of the angiotensin-converting enzyme9, while one study 
Assessed Factors, n= 190 n (%) Mean±SD* Range p**Gender Female 126 (66.3) - - -Male 64 (33.7) - - -Age at inclusion in the study (years-old) - 78.06±6.1 60.0-94.5 -Urea (mg/dL) Initial values - 40.27±15.9 11.00-118.0 0.777Final values - 40.73±16.5 14.00-115.9Yearly variation - 0.46±15.0 -79.00 to +89.0 -Creatinine (mg/dL) Initial values - 0.98±0.3 0.34-2.40 0.989Final values - 0.98±0.3 0.32-2.10Yearly variation - -0.01±0.2 -0.70 to +0.78 -Arterial hypertension 152 (80.0) - - -Systolic blood pressure (mmHg) Initial values - 131.89±17.4 90-180 <0.01Final values - 120.00±15.3 90-180Yearly variation - -11.89±17.3 -50 to +30 -Diastolic blood pressure (mmHg) Initial values - 78.53±10.1 60-110 <0.01Final values - 73.62±9.5 50-100Yearly variation - -4.91±10.4 -40 to +30 -Anti-hypertensive treatment with an angioten-sin-converting enzyme inhibitor (mg/day) Captopril 111 74.44±29.7 37.5-150.0 -Perindopril 3 6.67±2.3 4.0-8.0 -Enalapril 8 37.50±7.1 20.0-40.0 -*SD = standard deviation.**One-way analysis of variance with post-hoc Tukey test.
Table 1. Demographic aspects and variations of cardiovascular measures in one year
Table 2.  Genetic proportions for ACE genotypes and respective 
haplotypes
Assessed Genotypes and Haplotypes, n=190 n (%) p*
rs1800764 genotypes CC 51 (26.9) 0.148CT 85 (44.7)TT 54 (28.4)
rs4291 genotypes AA 89 (46.9) 0.077AT 74 (38.9)TT 27 (14.2)
ACE** haplotypes
rs1800764 CC / rs4291 AA 7   (3.7) -rs1800764 CC / rs4291 AT 17 (9.0) -rs1800764 CC / rs4291 TT 27 (14.2) -rs1800764 CT / rs4291 AA 28 (14.7) -rs1800764 CT / rs4291 AT 57 (30.0) -rs1800764 CT / rs4291 TT 0   (0.0) -rs1800764 TT / rs4291 AA 54 (28.4) -rs1800764 TT / rs4291 AT 0   (0.0) -rs1800764 TT / rs4291 TT 0   (0.0) -* Hardy-Weinberg equilibrium (Chi-square test).** ACE= angiotensin-converting enzyme gene.
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reported increased expression of  ACE  gene products with this 
allele15. Associations with the A allele of rs4291 have also been 
found for lower fasting glucose, while angiotensin-converting 
enzyme inhibitors have been associated with risk reduction of 
incident diabetes  mellitus16. On the other hand, the C allele of 
rs1800764 has been associated with increased risk for diabetic 
nephropathy2. These findings suggest independence between 
genetic pathways that mediate glucose homeostasis and renal 
function.
An earlier study found that people with dementia tend to 
experience greater late-life decreases in systolic and diastolic 
blood pressures17. This could explain the significant disparities in 
blood pressure variations in our findings, though our close follow-
up with aggressive anti-hypertensive therapy might also have 
affected these results. On the other hand, we found most genetic 
associations with creatinine rather than with urea levels. Since 
urea levels in blood may be affected by dietary protein and liver 
function, and not only by renal function, creatinine is considered 
a better indicator of glomerular filtration rates, thus explaining the 
outcomes we found.
Overall, 80% of our patients with dementia due to Alzheimer 
disease had arterial hypertension, confirming the burden of this 
risk factor over cardiovascular health in older people. Though we 
conveniently employed a cohort of patients who had dementia 
due to Alzheimer disease, the neurological diagnosis probably 
had little effect over the cardiovascular burden of our population. 
Nonetheless, earlier studies had confirmed the combined 
effect of cerebrovascular risk factors (arterial hypertension, 
diabetes mellitus, hypercholesterolemia, smoking and alcohol use) 
over earlier dementia onset18  and slower cognitive decline19  for 
people with dementia due to Alzheimer disease, possibly related 
to atherosclerotic mechanisms throughout life and enhanced 
cerebral perfusion pressure in late life, respectively. Despite the 
genetically mediated neuroprotective effects of angiotensin-
converting enzyme inhibitors in dementia due to Alzheimer 
disease5, we have now shown that therapy of arterial hypertension 
with angiotensin-converting enzyme inhibitors may also protect 
the glomerular filtration of creatinine for carriers of specific 
genotypes, thus justifying the preferential use of these drugs as 
anti-hypertensive therapy for such patients.
Limitations of this study include the fact that it was conducted 
in a single centre, with a short follow-up and no randomization, 
and lacking measurements of serum levels of the angiotensin-
converting enzyme or urinary creatinine clearance, as well as 
an evaluation of sarcopenia. Also, it is unknown whether the 
pharmacogenetic effects of angiotensin-converting enzyme 
inhibitors over urea and creatinine variations are either dose-
dependent or more significant when starting treatment or at 
any time during anti-hypertensive therapy, due to the fact that 
many patients were already under treatment when they were 
included in the study. We tried to minimize these limitations by 
keeping observers blinded to genetic data during the evaluations. 
Table 3.   Effects of angiotensin-converting enzyme inhibitors over variations of urea and creatinine in one year according to ACE 
genotypes and respective haplotypes.
Genotypes and represented haplotypes Urea variations (mean±SD* in mg/dL) Creatinine variations (mean±SD* in mg/dL)Users of ACEis** Non-users of ACEis** Total Users of ACEis** Non-users of ACEis** Total
rs1800764 genotypes CC -1.32±11.5 -0.90±12.7 -1.17±11.8 0.02±0.2 -0.05±0.2 -0.01±0.2CT 2.01±17.0 -2.61±19.1 0.60±17.7 -0.02±0.2 0.00±0.2 -0.01±0.2TT -2.10±11.9 6.66±13.1 1.79±13.1 -0.06±0.2 0.12±0.2 0.02±0.2
β (p)  -0.448 ( 0.563)‡  1.477 ( 0.315)†  0.016 ( 0.210)‡  0.016 ( 0.410)†
rs4291 genotypes AA 0.95±15.7 5.63±12.8 2.68±14.8 -0.01±0.2 0.12±0.2 0.04±0.2AT 0.06±13.8 -2.46±19.2 -0.89±15.9 -0.02±0.2 -0.04±0.2 -0.03±0.2TT -2.17±13.1 -5.86±9.0 -3.13±12.1 -0.02±0.2 -0.09±0.2 -0.04±0.2
β (p)  2.996 ( 0.127)‡  -3.074 ( 0.045)†  0.057 ( 0.029)‡  -0.044 ( 0.028)†
rs1800764cc/rs4291 AA Yes (n= 7) -3.00±9.4 0.00±14.7 -1.71±10.9 0.07±0.1 0.00±0.2 0.04±0.1No (n= 183) 0.21±14.7 1.17±16.1 0.55±15.2 -0.02±0.2 0.03±0.2 0.00±0.2
β (p)  1.219 ( 0.836)‡  -2.262 ( 0.697)†  0.029 ( 0.233)‡  0.045 ( 0.555)†
rs1800764cc/rs4291 AT Yes (n= 17) 1.33±8.8 3.10±14.8 2.16±11.7 0.07±0.1 -0.04±0.0 0.02±0.1No (n= 173) 0.00±14.9 0.85±16.2 0.30±15.3 -0.02±0.2 0.04±0.2 0.00±0.2
β (p)  0.909 ( 0.817)‡  1.867 ( 0.626)†  0.029 ( 0.256)‡  0.023 ( 0.647)†
rs1800764cc/rs4291 TT Yes (n= 27) -2.17±13.1 -5.86±9.0 -3.13±12.1 -0.02±0.2 -0.09±0.2 -0.04±0.2No (n= 163) -0.55±14.8 1.92±16.4 1.06±15.4 -0.02±0.2 0.04±0.2 0.01±0.2
β (p)  1.537 ( 0.386)‡  -4.185 ( 0.180)†  0.035 ( 0.170)‡  -0.045 ( 0.275)†
rs1800764CT/rs4291 AA Yes (n= 28) 5.82±20.0 4.33±12.1 5.50±18.4 0.03±0.2 0.15±0.2 0.06±0.2No (n= 162) -1.16±12.8 0.80±16.3 -0.41±14.2 -0.03±0.2 0.02±0.2 -0.01±0.2
β (p)  0.571 ( 0.124)‡  5.906 ( 0.054)†  0.024 ( 0.045)‡  0.067 ( 0.096)†
rs1800764CT/rs4291 AT Yes (n= 57) -0.25±14.8 -4.69±20.6 -1.81±17.0 -0.05±0.2 -0.04±0.2 -0.04±0.2No (n= 133) 0.25±14.5 3.53±13.1 1.44±14.0 0.00±0.2 0.06±0.2 0.02±0.2
β (p)  2.067 ( 0.360)‡  -3.244 ( 0.173)†  0.049 ( 0.035)‡  -0.063 ( 0.043)†
rs1800764TT/rs4291 AA Yes (n= 54) -2.10±11.9 6.66±13.1 1.79±13.1 -0.06±0.2 0.12±0.2 0.02±0.2No (n= 136) 0.82±15.3 -1.91±16.7 -0.06±15.7 -0.01±0.2 -0.02±0.2 -0.01±0.2
β (p)  0.496 ( 0.699)‡  1.855 ( 0.444)†  0.021 ( 0.185)‡  0.033 ( 0.294)†* SD =  standard deviation.** ACEis =  angiotensin-converting enzyme inhibitors.
‡ Coefficient for pharmacological treatment regarding multiple linear regressions with two degrees of freedom: genotype or haplotype variations and use or not of an angiotensin-converting enzyme inhibitor.† Coefficient for each T allele regarding simple linear regressions between genotypes or haplotypes and urea or creatinine variations.
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Nevertheless, to the best of our knowledge, this is the first study 
to evaluate the pharmacogenetic effects of angiotensin-converting 
enzyme inhibitors over age-related urea and creatinine variations.
Conclusions
We conclude that the effects of anti-hypertensive therapy with 
angiotensin-converting enzyme inhibitors over creatinine 
variations are genetically mediated and independent of systolic 
or diastolic blood pressure variations. Future studies should 
assess pharmacogenetic effects of angiotensin-converting enzyme 
inhibitors regarding variations in urinary creatinine clearance, 
and consider serum levels of the angiotensin-converting enzyme 
as a variable.
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